Core Viewpoint - The article discusses the brand integrity issues faced by Beijing Tongrentang, a historic Chinese medicine brand, due to its extensive licensing and outsourcing practices, which have led to product quality concerns and consumer confusion regarding authenticity [2][3][5]. Group 1: Brand Integrity and Licensing Issues - Beijing Tongrentang has faced significant backlash after a product, "99% High Purity Antarctic Krill Oil," was found to have no phospholipid content, raising questions about the quality of licensed products [2][3]. - The brand's licensing strategy has resulted in a proliferation of products under the Tongrentang name, leading to a situation where consumers struggle to differentiate between authentic and counterfeit products [3][7]. - The company has a complex network of over 400 subsidiaries, which complicates brand management and has led to various trademark disputes among different Tongrentang entities [7][9]. Group 2: Financial Performance and Market Strategy - Beijing Tongrentang's net profit for 2024 is projected to be 1.526 billion yuan, a decline of 8.54% year-on-year, marking the first negative growth in five years [9]. - The company has attempted to diversify its offerings by entering various sectors, including health supplements and direct sales, but this has raised concerns about brand dilution and consumer trust [8][9]. - The brand's efforts to modernize and appeal to younger consumers through new retail initiatives have been met with mixed results, highlighting the challenges of balancing traditional values with contemporary market demands [9].

Core Viewpoint - The article discusses the brand integrity issues faced by Beijing Tongrentang, a historic Chinese medicine brand, due to its extensive licensing and outsourcing practices, which have led to product quality concerns and consumer confusion regarding authenticity [2][5][12]. Group 1: Brand Integrity and Licensing Issues - Beijing Tongrentang has faced backlash after a product, "99% High Purity Antarctic Krill Oil," was found to have no phospholipid content, highlighting the risks associated with its brand licensing strategy [2][3]. - The company has a complex network of over 400 subsidiaries, leading to confusion among consumers about which products are genuinely from the original brand [9]. - The brand's licensing practices have resulted in a proliferation of products under the Tongrentang name, often produced by third-party manufacturers, which has diluted the brand's reputation [5][9]. Group 2: Financial Performance and Market Strategy - Beijing Tongrentang's net profit for 2024 is projected to be 1.526 billion yuan, a decline of 8.54% year-on-year, marking the first negative growth in five years [13]. - The company has attempted to modernize and attract younger consumers through new retail initiatives, but these efforts coexist with traditional practices that may undermine brand trust [12][13]. - The brand's expansion into direct sales of health products has raised concerns about the potential risks associated with this business model, which is often viewed negatively in China [12].

Core Viewpoint - The article discusses the potential risks and implications of the brand expansion strategy employed by Beijing Tongrentang, a well-known traditional Chinese medicine brand, highlighting issues related to product quality and brand integrity due to extensive licensing and outsourcing practices [1][3][10]. Group 1: Brand Integrity and Quality Issues - Beijing Tongrentang issued an apology regarding a product quality issue with its "99% high-purity Antarctic krill oil," which claimed a phospholipid content of 43% but was found to be 0% in actual tests [3][10]. - The brand's licensing model has led to a proliferation of products under the Tongrentang name, many of which are produced by third-party manufacturers, raising concerns about the authenticity and quality of these products [3][4][10]. - The complexity of brand ownership and licensing has resulted in confusion among consumers, as multiple entities within the Tongrentang group produce and sell products under similar names, leading to difficulties in distinguishing genuine products from counterfeit ones [6][7][10]. Group 2: Business Model and Market Strategy - The company has expanded its product offerings significantly, including health supplements and daily necessities, which has been referred to as the "Tongrentang Universe," but this expansion raises questions about brand dilution [3][4][10]. - Beijing Tongrentang Health Pharmaceutical has adopted a direct sales model for its health products, which is often associated with negative perceptions in the market, potentially risking the brand's reputation [10][12]. - The company is facing financial challenges, with a reported net profit of 1.526 billion yuan for 2024, marking an 8.54% decline year-on-year, indicating a need for strategic reevaluation amidst its aggressive expansion efforts [12]. Group 3: Consumer Trust and Brand Management - The article emphasizes the importance of establishing modern corporate governance and a robust authorization system to restore consumer trust in the Tongrentang brand, which has been built over a century [12]. - The dual approach of maintaining traditional practices while attempting to attract younger consumers through innovative strategies reflects the internal contradictions faced by the brand during its rapid expansion [12].

Group 1 - The core activity is a series of public welfare events initiated by Tongrentang Technology Company and Beijing Youth Daily, focusing on integrating traditional Chinese medicine (TCM) culture into rural revitalization efforts [1][21] - The events include winter health consultations and TCM cultural experience activities, aimed at promoting health and wellness through TCM knowledge [1][10] - The activities are designed to be engaging and educational, featuring hands-on experiences such as making traditional Chinese medicine pills and learning about herbal identification [3][5] Group 2 - In the community, TCM lectures cover winter health tips, dietary recommendations, and acupoint massage techniques, helping residents understand TCM practices [12][14] - The events also include interactive experiences, such as creating aromatic bracelets, which enhance community engagement with TCM culture [15] - Health consultations provided by experts from Tongrentang and Beijing University of Chinese Medicine address residents' health concerns, offering personalized advice and treatments [17][19] Group 3 - A separate initiative focuses on children with autism, providing TCM cultural experiences and health consultations tailored to their needs [21][23] - The program includes donations of essential rehabilitation materials and aims to improve the well-being of special needs children through TCM therapies [21][23] - The immersive activities allow participants to experience TCM culture through multiple senses, fostering a deeper appreciation for its benefits [23]

及其对照指纹图谱（ R ） 图15 批加味逍遥丸指纹图谱 维度升级：本项目研究将质量监控从单一指标升级为覆盖全方君臣佐使的"功效成分群"定量模式，来源 于君药（柴胡）、臣药（牡丹皮、栀子）及佐使药（白芍、甘草）的八种测定成分经证实与加味逍遥丸 疏肝清热等核心功效直接相关，标志着质量控制从"成分检测"迈向"功效关联"的科学新阶段。 近日，由同仁堂与北京中医药大学联合开展的加味逍遥丸质量评价研究取得重要成果。相关论文已在中 文核心期刊《西北药学杂志》正式收录，该项研究创新构建了"双维度指纹图谱-功效成分定量"质控新 模式，有效破解了中药复方多类型成分、尤其是弱紫外吸收核心成分同步检测的技术难题。 此项研究是同仁堂"守正创新"的典范，通过科技创新为百年古方注入现代科学内涵。新方法将为产品的 安全、有效与优质稳定提供更强技术保障，也为中药行业复方制剂的精准质控提供了创新性的"同仁堂 方案"。同仁堂将继续以科技赋能传统，以品质守护健康，助力中药产业高质量发展。 方法首创：成功利用HPLC-PDA-ELSD双检测器联用技术，首次实现对加味逍遥丸中紫外强吸收成分 （如栀子苷）与弱紫外吸收核心功效成分（如柴胡皂苷A、D）的同 ...

Core Viewpoint - The clinical study of Angong Jiangya Wan, conducted by a team from Capital Medical University and eight medical institutions, provides new evidence for the treatment of secondary hypertension with liver yang hyperactivity, highlighting its clinical value and application prospects [1]. Group 1: Blood Pressure Control Effect - The study, a multi-center, randomized, double-blind, placebo-controlled trial, included 240 patients and demonstrated a significant reduction in systolic/diastolic blood pressure by 15.58±10.16/9.72±7.41 mmHg, which is clinically meaningful for secondary hypertension patients [1]. - The blood pressure control rate reached 31.86%, validating the efficacy of Angong Jiangya Wan as an adjunct treatment for patients whose blood pressure remains uncontrolled after standard therapy [1]. Group 2: Symptom Improvement and Synergistic Effect - Angong Jiangya Wan showed a clinical improvement rate of up to 94.62% for core symptoms such as dizziness and headache, significantly outperforming the control group in both TCM syndrome scoring and quality of life scoring [2]. - The drug demonstrated stable synergistic effects when used in combination with mainstream treatment regimens, such as CCB+ARB and CCB+β-blockers, indicating its compatibility without the need to alter existing treatment frameworks [2]. Group 3: Safety and Academic Significance - No adverse events were reported during the trial, confirming the safety of Angong Jiangya Wan in combination therapy, which is crucial for long-term hypertension management [2]. - The study employs an internationally recognized evidence-based medicine approach to validate the efficacy of traditional Chinese medicine, providing a model for the modernization of TCM and the integration of Chinese and Western medicine in hypertension treatment [3].

同仁堂聚焦"满足行业需求的中药质控体系缺乏"的行业痛点，与北京中医药大学合作，在功效物质明 晰、质量控制指标筛选等方面建立了一系列专有技术和方法，系统阐明了大黄、人参等中药饮片所含的 化学成分以及体内代谢转化成分，进而精准表征了大黄蛰虫丸、人参养荣丸、人参健脾丸等中药复方的 物质基础，阐明了中药质量形成机理。通过内控标准提升和技术升级改造，促进了产品质量的进一步提 升。 近日，中华中医药学会公示了2025年度中华中医药学会科学技术奖评审结果。由北京中医药大学高晓燕 教授牵头，联合同仁堂等6家单位共同申报的《中药功效物质高效发现技术体系创新与产业化应用》项 目获科技进步三等奖。 阐明中药功效物质是构建中药整体质控标准体系、保障临床用药和产业发展的关键。几十年来，随着中 药现代化进程的发展，在中药功效成分研究领域取得了可喜进展，但依然无法克服其片面性、假阳性、 低效性等问题，制约了中药标准化和国际化。该项目是以中医药传承与创新发展的国家重大发展战略为 牵引，针对制约中药功效物质发现全面性和准确性的若干技术问题，朝向中药化学成分高效解析、功效 指标精准量化和功效物质准确辨识三个关键环节开展研究：利用高分辨质谱技术， ...

Core Insights - Beijing Tongrentang has made significant progress in the safety research of traditional Chinese medicine for depression, with results published in key journals [1][2] - The research provides scientific evidence for the clinical safety of medication for postpartum and adolescent depression patients, highlighting the importance of rational drug use [1][2] Group 1: Research Achievements - The studies on the safety of Baijitian oligosaccharide capsules were conducted in collaboration with the National Drug Safety Evaluation and Monitoring Center, focusing on non-clinical safety evaluations for nursing and juvenile animals [2] - The research involved administering doses up to 50 times the maximum daily human dosage, with no abnormal findings in various health indicators of the test animals, confirming the high safety of the capsules [2] Group 2: Product Development and Recognition - Baijitian oligosaccharide capsules, developed jointly with the Academy of Military Medical Sciences, are classified as a new type of traditional Chinese medicine and have received multiple invention patents and the First Prize for Scientific and Technological Progress in Beijing [1] - The product has been included in nine expert consensus and treatment guidelines, establishing it as a core therapeutic drug for mild to moderate depression [1] Group 3: Commitment to Safety and Innovation - The company emphasizes patient needs and adheres to strict standards in product quality, utilizing scientific methods to deepen safety research and ensure medication safety [2] - Beijing Tongrentang's long-standing philosophy of meeting health needs continues to drive innovation in traditional Chinese medicine, contributing to the high-quality development of mental health services in China [2]

中国经济网12月22日讯12月19日，国家医疗保障局发布第15期价格招采信用评价"特别严重(失信)"和"严 重(失信)"评定结果。截至2025年10月1日，70家医药企业被各省份评级为"特别严重(失信)"和"严重(失 信)"，涉及广州一品红（300723）制药有限公司、石家庄四药有限公司、通用(上海)医疗器材有限公 司、山西振东道地药材开发有限公司、北京同仁堂（600085）(亳州)饮片有限责任公司、安徽冯了性中 药材饮片有限公司等。 国家医疗保障局于2020年建立价格招采信用评价制度，对法院判决、有关部门查处的医药购销行贿、带 金销售等问题突出的企业开展失信评级，并采取限制挂网、配送等约束措施。价格招采信用评级主要依 据行贿金额、不正当价格行为、扰乱集中采购秩序等严重程度进行确定。比如，累计行贿金额1万元以 上为"失信"，累计行贿金额50万元以上为"严重失信"，累计行贿金额100万元以上为"特别严重失信"。 | 医者 | 企业名称 | 评级 | 评定结果 | 酱注 | 评定 标准 | | --- | --- | --- | --- | --- | --- | | | | 省份 | | | | | 1 | 重 ...

Core Insights - The Shanghai Municipal Medical Procurement Management Office has released a list of drug varieties for public bidding and procurement supervision for September 2025, highlighting products that exceed the "yellow line" threshold, did not pass fairness assessments, or are under close monitoring [1][10] Group 1: Drug Varieties - The list includes exclusive products such as Ma Ren Run Chang Soft Capsules, Yunnan Baiyao Aerosol, and Bu Xin Qi Oral Liquid [1] - New applications exceeding the "yellow line" include exclusive products from Beijing Tongrentang and Yunnan Baiyao Group [1] - Existing products on the "yellow line" list include exclusive items like Regaglinide Metformin Tablets (II) from Zhejiang Tailisen Pharmaceutical [1] Group 2: Regulatory Framework - Since September 2018, Shanghai has implemented a public bidding mechanism for drug procurement, utilizing a pricing inquiry model based on "information push, green line reference, yellow line reminder, and red line interception" [9] - Starting from June 2024, the list will also include products that did not pass fairness assessments and those under close monitoring [9] Group 3: Procurement Guidelines - The Shanghai Municipal Medical Procurement Management Office emphasizes that the published list serves as a reminder for medical institutions to price reasonably based on market supply and demand, ensuring clinical needs are met while avoiding unreasonable price adjustments [10]